Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06070649 · ClinicalTrials.gov registry record · Phase 1
The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)
A Phase 1 study of Alcohol Use Disorder (AUD) and Alcohol-Related Disorders, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
- 1
- Study location
NCT06070649 is a Phase 1 study of Alcohol Use Disorder (AUD) and Alcohol-Related Disorders that is actively recruiting participants, run by Yale University. The registered enrollment target is 63 participants, below the 1,822-participant average among 30 other Alcohol Use Disorder (AUD) trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06070649, a Phase 1 study of Alcohol Use Disorder (AUD) and Alcohol-Related Disorders, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
- 1
- Study location
Study Summary
This proposed study is a double-blind, randomized, placebo-controlled, parallel-group, laboratory study to determine the effects of DMT, plus psychotherapy, on Alcohol Use Disorder.
Conditions Studied
Interventions
- DRUG 0.3mg/kg/min Dimethyltryptamine + Normal Saline infusion
- DRUG 0.2 mg/kg/min + Dimethyltryptamine 0.01mg/kg/min infusion
- DRUG 25 mg Diphenhydramine (5 min) + Normal Saline
Study Locations (1)
Connecticut
- Connecticut Mental Health Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2025-08-04 |
| Est. Completion | 2026-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06070649
The ClinicalTrials.gov registry entry for NCT06070649 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,822-participant average among 30 other Alcohol Use Disorder (AUD) trials with a reported enrollment target (97% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Alcohol Use Disorder (AUD) appearing as the primary indexed condition, and to 3 interventions - of which 0.3mg/kg/min Dimethyltryptamine + Normal Saline infusion is the first listed.
NCT06070649 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT06070649 about?
NCT06070649 is a clinical study titled "The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)". This proposed study is a double-blind, randomized, placebo-controlled, parallel-group, laboratory study to determine the effects of DMT, plus psychotherapy, on Alcohol Use Disorder.
What is the current status of trial NCT06070649?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2025-08-04. Estimated completion is 2026-08-01.
What conditions does trial NCT06070649 study?
This clinical trial studies the following conditions: Alcohol Use Disorder (AUD), Alcohol-Related Disorders, Alcohol Use.
What interventions are being tested in trial NCT06070649?
The interventions under investigation include: 0.3mg/kg/min Dimethyltryptamine + Normal Saline infusion (DRUG), 0.2 mg/kg/min + Dimethyltryptamine 0.01mg/kg/min infusion (DRUG), 25 mg Diphenhydramine (5 min) + Normal Saline (DRUG).
Who is sponsoring clinical trial NCT06070649?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06070649 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder (AUD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms
RECRUITING · Phase 1
-
Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study
RECRUITING · Phase 1
-
Diclofenac Dose Response Study
RECRUITING · Phase 1
-
Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers
RECRUITING · Phase 1
-
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
RECRUITING · Phase 2
-
Recovery Through Inhibitory Learning, Self-Efficacy Building, Problem Solving, and Community Building
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.